Veracyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Veracyte and other ETFs, options, and stocks.

About VCYT

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. 

CEO
Marc A. Stapley
CEOMarc A. Stapley
Employees
824
Employees824
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2006
Founded2006
Employees
824
Employees824

VCYT Key Statistics

Market cap
3.42B
Market cap3.42B
Price-Earnings ratio
114.04
Price-Earnings ratio114.04
Dividend yield
Dividend yield
Average volume
754.76K
Average volume754.76K
High today
$43.58
High today$43.58
Low today
$41.23
Low today$41.23
Open price
$41.73
Open price$41.73
Volume
572.19K
Volume572.19K
52 Week high
$50.71
52 Week high$50.71
52 Week low
$22.61
52 Week low$22.61

Stock Snapshot

Veracyte(VCYT) stock is priced at $43.30, giving the company a market capitalization of 3.42B. It carries a P/E multiple of 114.04.

During the trading session on 2026-01-22, Veracyte(VCYT) shares reached a daily high of $43.58 and a low of $41.23. At a current price of $43.30, the stock is +5.0% higher than the low and still -0.6% under the high.

Trading volume for Veracyte(VCYT) stock has reached 572.19K, versus its average volume of 754.76K.

Over the past 52 weeks, Veracyte(VCYT) stock has traded between a high of $50.71 and a low of $22.61.

Over the past 52 weeks, Veracyte(VCYT) stock has traded between a high of $50.71 and a low of $22.61.

Analyst ratings

77%

of 13 ratings
Buy
76.9%
Hold
15.4%
Sell
7.7%

People also own

Based on the portfolios of people who own VCYT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.